USPTO Examiner GROSS CHRISTOPHER M - Art Unit 1684

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18800910MACROMOLECULE ANALYSIS EMPLOYING NUCLEIC ACID ENCODINGAugust 2024December 2024Allow410NoNo
18764943N-TERMINAL MODIFIER AGENTS AND BINDERS FOR TREATING AND ANALYZING PEPTIDESJuly 2024July 2025Allow1221YesNo
18764600EFFICIENTLY CHARACTERIZING PROTEIN-PROTEIN INTERACTIONSJuly 2024October 2024Allow300YesNo
18660053MACROMOLECULE ANALYSIS EMPLOYING NUCLEIC ACID ENCODINGMay 2024June 2025Allow1400NoNo
18659334MACROMOLECULE ANALYSIS EMPLOYING NUCLEIC ACID ENCODINGMay 2024March 2025Allow1000NoNo
18610717METHODS AND COMPOSITIONS USING ONE-SIDED TRANSPOSITIONMarch 2024March 2025Allow1210NoNo
18590738ARRAYS INCLUDING A RESIN FILM AND A PATTERNED POLYMER LAYERFebruary 2024April 2025Allow1410NoNo
18433344METHOD FOR PREDICTING THE OFF-TARGET BINDING OF A PEPTIDE WHICH BINDS TO A TARGET PEPTIDE PRESENTED BY A MAJOR HISTOCOMPATIBILITY COMPLEXFebruary 2024March 2026Abandon2520NoNo
18409174METHODS, COMPOSITIONS, AND SYSTEMS FOR SPATIAL ANALYSIS OF ANALYTES IN A BIOLOGICAL SAMPLEJanuary 2024May 2025Allow1610YesNo
18402273METHODS OF SELECTING BINDING REAGENTSJanuary 2024January 2026Allow2540YesNo
18388735PROCESSES AND SYSTEMS FOR PREPARATION OF NUCLEIC ACID SEQUENCING LIBRARIES AND LIBRARIES PREPARED USING SAMENovember 2023October 2025Allow2320YesNo
18492069MAMMALIAN CELLS AND METHODS FOR ENGINEERING THE SAMEOctober 2023November 2024Allow1312YesNo
18484871HIGH THROUGHPUT PROTEIN-PROTEIN INTERACTION SCREENING IN YEAST LIQUID CULTUREOctober 2023November 2025Abandon2620NoNo
18482755PEPTIDE DEFICIENT-MHC CLASS I/CHAPERONE COMPOSITIONS AND METHODSOctober 2023January 2026Allow2720YesNo
18355946SINGLE CELL ANALYSIS OF TRANSPOSASE ACCESSIBLE CHROMATINJuly 2023April 2025Allow2120NoNo
18329296MAMMALIAN CELL LINE FOR PROTEIN PRODUCTION AND LIBRARY GENERATIONJune 2023November 2024Allow1710YesNo
18324720METHOD FOR TRANSPOSASE MEDIATED SPATIAL TAGGING AND ANALYZING GENOMIC DNA IN A BIOLOGICAL SAMPLEMay 2023November 2025Abandon2950NoNo
18252773CELL-FREE EXPRESSION OF ANTIBODIES, ANTIGEN-BINDING FRAGMENTS THEREOF, AND ANTIBODY DERIVATIVESMay 2023March 2026Allow3400NoNo
18131577Deep Sequencing Profiling of TumorsApril 2023January 2026Allow3340YesNo
18190288NANOPORE DEVICE AND METHODS OF BIOSYNTHESIS USING SAMEMarch 2023January 2024Allow1000NoNo
18178367METHODS, COMPOSITIONS, AND SYSTEMS FOR CAPTURING PROBES AND/OR BARCODESMarch 2023December 2024Allow2240NoNo
18099913PROBE SET FOR ANALYZING A DNA SAMPLE AND METHOD FOR USING THE SAMEJanuary 2023June 2025Allow2930YesNo
18055297Fusion Proteins Comprising an Engineered Knottin Peptide and Uses ThereofNovember 2022December 2024Allow2620YesNo
18050912FLEXIBLE SUBSTRATES FOR NUCLEIC ACID SYNTHESISOctober 2022February 2025Abandon2830YesNo
17964771MICROFLUIDIC DEVICE FOR STORAGE AND WELL-DEFINED ARRANGEMENT OF DROPLETSOctober 2022August 2025Abandon3410NoNo
17934829METHODS AND DEVICES FOR DETECTION OF PERIPHERAL MEMBRANE PROTEIN INTERACTIONS USING NONLINEAR OPTICAL TECHNIQUESSeptember 2022July 2025Abandon3410NoNo
17899860High-Throughput Screening Methods to Identify Small Molecule TargetsAugust 2022May 2024Allow2110NoNo
17820409METHOD OF IDENTIFYING BIOMARKERS OF NEUROLOGICAL DISEASES AND DIAGNOSIS OF NEUROLOGICAL DISEASESAugust 2022March 2026Abandon4310NoNo
17816691METHODS AND SYSTEMS FOR MASK ALIGNMENT IN MANUFACTURING PROCESS OF ARRAYSAugust 2022June 2025Abandon3501NoNo
17815256COMPOSITIONS AND METHODS FOR TREATMENTJuly 2022October 2025Allow3901YesNo
17761383METHODS FOR DETERMINING THE SEVERITY AND PROGNOSIS OF RSV INFECTIONMarch 2022February 2026Abandon4710NoNo
17690386METHOD FOR SYNTHESIZING DNAMarch 2022November 2024Abandon3211NoNo
17683059GENE SEQUENCING CHIP AND GENE SEQUENCING METHODFebruary 2022April 2025Allow3710NoNo
17680101PROTEINS TARGETING ORTHOLOGSFebruary 2022January 2026Allow4730NoNo
17629398TEST STRIP AND METHOD FOR DETECTING AMYLOID BETA IN URINEJanuary 2022September 2025Allow4410YesNo
17624295BIOMARKERS FOR IRRITABLE BOWEL SYNDROMEDecember 2021May 2025Allow4000NoNo
17618811IMPROVEMENTS IN NUCLEIC ACID SEQUENCINGDecember 2021January 2026Allow4910NoNo
17542196BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXESDecember 2021January 2026Allow5030YesNo
17528456ASSAYS FOR ANTIMICROBIAL ACTIVITY AND APPLICATIONS THEREOFNovember 2021October 2025Allow4710NoNo
17453336METHODS AND COMPOSITIONS FOR DIAGNOSTICALLY-RESPONSIVE LIGAND-TARGETED DELIVERY OF THERAPEUTIC AGENTSNovember 2021December 2025Abandon4910NoNo
17608027BIOMARKER PANEL FOR SEPSIS ENCEPHALOPATHYNovember 2021January 2026Allow5111NoNo
17607801High-Throughput Screening Methods to Identify Small Molecule TargetsOctober 2021November 2025Abandon4920NoNo
17607669METHOD FOR PERITONEAL METASTATIC CELL DETECTION AND ISOLATION THEREOFOctober 2021January 2026Allow5111YesNo
17447416MODULAR CHEMIRESISTIVE SENSOR FOR REAL-TIME ETHYLENE MONITORINGSeptember 2021April 2025Allow4300NoNo
17431193METHODS FOR DETERMINING KINETIC PARAMETERS OF A REACTION BETWEEN ANALYTE AND LIGANDSAugust 2021June 2025Allow4601YesNo
17392534MIRNA FINGERPRINT IN THE DIAGNOSIS OF LUNG CANCERAugust 2021October 2025Abandon5001NoNo
17053792SOLID-PHASE SURFACE AND SOLUTION MOTION MODE AND MOTION DEVICEJuly 2021July 2025Abandon5611NoNo
17413148AMPLIFICATION METHODS AND SYSTEMS FOR MERFISH AND OTHER APPLICATIONSJune 2021July 2025Allow4910YesNo
17296723SYSTEM AND METHOD FOR ANALYZING EXTRACELLULAR VESICLES WITH AN OPTICAL BIOSENSORMay 2021January 2026Allow5630YesNo
17181659DIGITAL LSPR FOR ENHANCED ASSAY SENSITIVITYFebruary 2021December 2025Abandon5821YesNo
17175606METHODS AND DEVICES FOR DETECTION AND ACQUISITION OF BIOMARKERSFebruary 2021January 2025Abandon4810NoNo
17267827DROPLET ARRAYS FOR DETECTION AND QUANTIFICATION OF ANALYTESFebruary 2021July 2025Abandon5320NoNo
17172029METHODS AND COMPOSITIONS FOR SEQUENCINGFebruary 2021November 2025Abandon5840NoNo
17145197IMMUNOASSAY DETECTION DEVICE WITH TEST STRIP ACCOMMODATED IN A CAPILLARY TUBEJanuary 2021July 2025Abandon5420NoNo
17258001METHODS AND COMPOSITIONS FOR ANALYZING PLATELETS BY MASS CYTOMETRYJanuary 2021November 2024Abandon4610NoNo
17141682Methods, Systems and Compositions Thereof for Nucleic Acid Library Quality Control and QuantificationJanuary 2021May 2025Abandon5241NoNo
17055803Devices, Systems, and Methods of Electronic Modulation of Polymerase for DNA SynthesisNovember 2020August 2024Allow4531YesNo
17082940METHODS OF SINGLE-POLYPEPTIDE SEQUENCING AND RECONSTRUCTIONOctober 2020November 2024Abandon4821NoNo
17079959COMPOSITIONS AND METHODS FOR THERAPEUTICS PRESCREENINGOctober 2020March 2025Allow5350YesNo
17025011Methods, Compositions, and Systems for Classification of Genetic Variants of Unknown SignificanceSeptember 2020July 2025Abandon5831NoNo
16969328KIT OR DEVICE AND METHOD FOR DETECTING DEMENTIAAugust 2020September 2025Allow6021YesNo
16968512ARRAY-BASED CYCLIC PEPTIDE LIBRARIESAugust 2020November 2024Abandon5260NoNo
16943067STABILIZED IMMUNOGLOBULIN DOMAINSJuly 2020November 2024Allow5211NoNo
16770693SCREENING METHOD FOR TELOMERASE REVERSE TRANSCRIPTASE (TERT) PHOSPHORYLATION INHIBITORSJune 2020November 2025Allow6021NoNo
16548143IN VITRO DNA WRITING FOR INFORMATION STORAGEAugust 2019November 2024Abandon6041YesNo
16385735MOVABLE TYPE METHOD APPLIED TO PROTEIN-LIGAND BINDINGApril 2019September 2024Allow6010YesNo
16302345METHODS FOR IDENTIFICATION OF SAMPLESNovember 2018January 2025Allow6080YesNo
16074128NUCLEIC ACIDS ENCODING CHIMERIC POLYPEPTIDES FOR LIBRARY SCREENINGJuly 2018April 2025Allow6061YesNo
15485109Library Quantitation And QualificationApril 2017September 2025Allow60111YesNo
15212215METHODS OF SELECTING ANTIBODIES AND ANTIBODY FRAGMENTSJuly 2016May 2025Allow6060YesYes
15131101APPARATUS FOR ASSAY, SYNTHESIS AND STORAGE, AND METHODS OF MANUFACTURE, USE, AND MANIPULATION THEREOFApril 2016January 2018Allow2120YesNo
14993792PHAGE MICROARRAY PROFILING OF THE HUMORAL RESPONSE TO DISEASEJanuary 2016April 2018Allow2701YesNo
14823571MANIPULATION OF MICROPARTICLES IN MICROFLUIDIC SYSTEMSAugust 2015January 2017Allow1810YesNo
14414916MULTI-SENSOR ARRAY COMPOUND AND METHODS OF USE THEREOFJanuary 2015January 2018Allow3611YesNo
14073653PS-SPCL SEARCHING APPARATUS AND METHOD USING SURFACE PLASMON RESONANCENovember 2013April 2018Allow5321NoNo
13761968TYROSINE KINASE BIOSENSORS AND METHODS OF USEFebruary 2013August 2016Allow4331NoNo
13487605PROBE ARRAY BASE, METHOD FOR MANUFACTURING PROBE ARRAY BASE, METHOD FOR MANUFACTURING PROBE ARRAYJune 2012January 2014Allow1921YesNo
13463212BETA-AMINO ACIDSMay 2012February 2014Allow2111YesNo
13396352Methods and Compositions for the Target-localized Anchoring of Detectable LabelFebruary 2012June 2016Allow5241YesNo
13365554METHODS AND KITS USING EXTENDED RHODAMINE DYESFebruary 2012August 2013Allow1922YesNo
13289542Ligand Libraries for Screening GPCRsNovember 2011January 2013Abandon1411NoNo
13207486IDENTIFYING ANTIGEN CLUSTERS FOR MONITORING A GLOBAL STATE OF AN IMMUNE SYSTEMAugust 2011December 2013Allow2811YesNo
12928312High throughput system for isolation, growth, and detection of lipid inclusions in bacteriaDecember 2010August 2015Allow5621YesNo
12848888Stamping Apparatus For Biochips and Method For Operation ThereofAugust 2010May 2015Allow5821YesNo
12465719NOVEL DIARYLPHOSPHINE-CONTAINING COMPOUNDS, PROCESSES OF PREPARING SAME AND USES THEREOF AS TRIDENTATE LIGANDSMay 2009March 2013Allow4621YesNo
12162799Novel Silane Compounds and Their Use in Functionalizing Solid Supports and Immobilizing Biological Molecules on These SupportsAugust 2008July 2016Allow6061NoNo
11884066Method and Array for the Replication and Analysis of Nucleic AcidsJune 2008September 2015Allow6042YesNo
12133190MASSIVELY PARALLEL SYNTHESIS OF BIOPOLYMERIC ARRAYSJune 2008July 2016Allow6031NoNo
11908223QUANTUM DOT TEMPLATE FOR FAST AND SIMULTANEOUS DETECTION OF DIFFERENT INFECTIOUS AGENTSMay 2008December 2013Allow6032YesNo
11856099METHOD AND COMPOSITION FOR DETECTING PROTEIN-PROTEIN AND PROTEIN-NUCLEIC ACID INTERACTIONSSeptember 2007September 2013Allow6021YesNo
10594182POLYMER PARTICLEJuly 2007December 2010Allow5111YesNo
11758735METHOD FOR DETECTING TARGET BIOLOGICAL MATERIAL USING DNA BARCODESJune 2007November 2010Allow4111YesNo
11744112NUCLEIC ACID SAMPLE PURIFICATION AND ENRICHMENT WITH A THERMO-AFFINITY MICROFLUIDIC SUB-CIRCUITMay 2007March 2011Allow4622YesNo
11404807METHOD FOR SCREENING ANTI-ADHERENT COMPOUNDS ON POLYMERS FOR PREVENTING BIOFILM FORMATIONApril 2006June 2009Allow3831YesNo
10563463CUCURBITURIL DERIVATIVE-BONDED SOLID SUBSTRATE AND BIOCHIP USING THE SAMEJanuary 2006July 2010Allow5431NoNo
10540396PHOTOACTIVATABLE TWO-STAGE PROTECTIVE GROUPS FOR THE SYNTHESIS OF BIOPOLYMERSSeptember 2005February 2010Allow5621YesNo
11231309PRINTING LIQUID SOLUTION ARRAYS FOR INORGANIC COMBINATORIAL LIBRARIESSeptember 2005January 2011Abandon6063YesYes
11223825COMBINATORIAL ARTIFICIAL RECEPTORS INCLUDING PEPTIDE BUILDING BLOCKSSeptember 2005December 2010Allow6002YesNo
11156653PNA CHIP USING PLASTIC SUBSTRATE COATED WITH EPOXY GROUP-CONTAINING POLYMER, METHOD OF MANUFACTURING THE PNA CHIP, AND METHOD OF DETECTING SINGLE NUCLEOTIDE POLYMORPHISM USING THE PNA CHIPJune 2005December 2009Allow5421YesYes
11033416HETEROCYCLIC COMPOUNDS CONTAINING A NINE-MEMBERED CARBON-NITROGEN RINGJanuary 2005March 2009Allow5050YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GROSS, CHRISTOPHER M.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
4
Examiner Affirmed
1
(25.0%)
Examiner Reversed
3
(75.0%)
Reversal Percentile
88.9%
Higher than average

What This Means

With a 75.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
14
Allowed After Appeal Filing
6
(42.9%)
Not Allowed After Appeal Filing
8
(57.1%)
Filing Benefit Percentile
70.4%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 42.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner GROSS, CHRISTOPHER M - Prosecution Strategy Guide

Executive Summary

Examiner GROSS, CHRISTOPHER M works in Art Unit 1684 and has examined 84 patent applications in our dataset. With an allowance rate of 77.4%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 54 months.

Allowance Patterns

Examiner GROSS, CHRISTOPHER M's allowance rate of 77.4% places them in the 44% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by GROSS, CHRISTOPHER M receive 2.98 office actions before reaching final disposition. This places the examiner in the 86% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by GROSS, CHRISTOPHER M is 54 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +43.1% benefit to allowance rate for applications examined by GROSS, CHRISTOPHER M. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 22.3% of applications are subsequently allowed. This success rate is in the 28% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 18.5% of cases where such amendments are filed. This entry rate is in the 22% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 2% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 73.3% of appeals filed. This is in the 62% percentile among all examiners. Of these withdrawals, 45.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 84.2% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 29.8% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.